A chemical genetic approach identifies piperazine antipsychotics as promoters of CNS neurite growth on inhibitory substrates

Molecular and Cellular Neuroscience

Volumn 50, Issue 2, 2012, Pages 125-135

  Johnstone, Andrea L ^a   Reierson, Gillian W ^a   Smith, Robin P ^a   Goldberg, Jeffrey L ^a,b   Lemmon, Vance P ^a   Bixby, John L ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Antipsychotics; Chondroitin sulfate proteoglycans; Myelin; Phenothiazine; Piperazine; Prochlorperazine; Regeneration; Trifluoperazine

Indexed keywords

ASTEMIZOLE; CALMODULIN; CLOMIPRAMINE; CORTICOSTERONE; DESIPRAMINE; DILAZEP; DOPAMINE RECEPTOR BLOCKING AGENT; F05; FENDILINE; FLUPHENAZINE; FLUTICASONE; GELDANAMYCIN; LAMININ; MOMETASONE FUROATE; NEUROLEPTIC AGENT; NICLOSAMIDE; PHENOTHIAZINE DERIVATIVE; PIPERAZINE; PROCHLORPERAZINE; TERFENADINE; TETRANDRINE; TRIFLUOPERAZINE; UNCLASSIFIED DRUG;

ARTICLE; CELL STRAIN MCF 7; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DOSE RESPONSE; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; IN VITRO STUDY; NERVE FIBER GROWTH; NERVE FIBER REGENERATION; PRIORITY JOURNAL; RETINA GANGLION CELL; SIGNAL TRANSDUCTION;

ANIMALS; ANTIPSYCHOTIC AGENTS; BRAIN; CALCIUM SIGNALING; CELL LINE, TUMOR; CELLS, CULTURED; CHO CELLS; CHONDROITIN SULFATE PROTEOGLYCANS; CRICETINAE; CRICETULUS; GENE EXPRESSION PROFILING; HUMANS; NEURITES; NEURONS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHENOTHIAZINES; PIPERAZINES; RATS; REGENERATION;

PHAPS;

EID: 84861388460     PISSN: 10447431     EISSN: 10959327     Source Type: Journal    
DOI: 10.1016/j.mcn.2012.04.008     Document Type: Article

References (98)

1. Asher R.A., Morgenstern D.A., Fidler P.S., Adcock K.H., Oohira A., Braistead J.E., Levine J.M., Margolis R.U., Rogers J.H., Fawcett J.W. Neurocan is upregulated in injured brain and in cytokine-treated astrocytes. J. Neurosci. 2000, 20:2427-2438.
2. Atwal J.K., Pinkston-Gosse J., Syken J., Stawicki S., Wu Y., Shatz C., Tessier-Lavigne M. PirB is a functional receptor for myelin inhibitors of axonal regeneration. Science 2008, 322:967-970.
3. Banker G.A., Cowan W.M. Rat hippocampal neurons in dispersed cell culture. Brain Res. 1977, 126:397-402.
4. Barnes A.P., Polleux F. Establishment of axon-dendrite polarity in developing neurons. Annu. Rev. Neurosci. 2009, 32:347-381.
5. Barres B.A., Silverstein B.E., Corey D.P., Chun L.L. Immunological, morphological, and electrophysiological variation among retinal ganglion cells purified by panning. Neuron 1988, 1:791-803.
6. Benitez-King G., Ortiz-Lopez L., Jimenez-Rubio G., Ramirez-Rodriguez G. Haloperidol causes cytoskeletal collapse in N1E-115 cells through tau hyperphosphorylation induced by oxidative stress: Implications for neurodevelopment. Eur. J. Pharmacol. 2010, 644:24-31.
7. Blackmore M.G., Moore D.L., Smith R.P., Goldberg J.L., Bixby J.L., Lemmon V.P. High content screening of cortical neurons identifies novel regulators of axon growth. Mol. Cell. Neurosci. 2010, 44:43-54.
8. Braconi C., Meng F., Swenson E., Khrapenko L., Huang N., Patel T. Candidate therapeutic agents for hepatocellular cancer can be identified from phenotype-associated gene expression signatures. Cancer 2009, 115:3738-3748.
9. Bradbury E.J., Moon L.D., Popat R.J., King V.R., Bennett G.S., Patel P.N., Fawcett J.W., McMahon S.B. Chondroitinase ABC promotes functional recovery after spinal cord injury. Nature 2002, 416:636-640.
10. Bradke F., Dotti C.G. Neuronal polarity: vectorial cytoplasmic flow precedes axon formation. Neuron 1997, 19:1175-1186.
11. Bregman B.S. Regeneration in the spinal cord. Curr. Opin. Neurobiol. 1998, 8:800-807.
12. Cafferty W.B., Duffy P., Huebner E., Strittmatter S.M. MAG and OMgp synergize with Nogo-A to restrict axonal growth and neurological recovery after spinal cord trauma. J. Neurosci. 2010, 30:6825-6837.
13. Cai D., Shen Y., De Bellard M., Tang S., Filbin M.T. Prior exposure to neurotrophins blocks inhibition of axonal regeneration by MAG and myelin via a cAMP-dependent mechanism. Neuron 1999, 22:89-101.
14. Chen S., Owens G.C., Edelman D.B. Dopamine inhibits mitochondrial motility in hippocampal neurons. PLoS One 2008, 3:e2804.
15. Chen M.H., Yang W.L., Lin K.T., Liu C.H., Liu Y.W., Huang K.W., Chang P.M., Lai J.M., Hsu C.N., Chao K.M., Kao C.Y., Huang C.Y. Gene expression-based chemical genomics identifies potential therapeutic drugs in hepatocellular carcinoma. PLoS One 2011, 6:e27186.
16. Claerhout S., Lim J.Y., Choi W., Park Y.Y., Kim K., Kim S.B., Lee J.S., Mills G.B., Cho J.Y. Gene expression signature analysis identifies vorinostat as a candidate therapy for gastric cancer. PLoS One 2011, 6:e24662.
17. Collins F.S. Mining for therapeutic gold. Nat. Rev. Drug Discov. 2011, 10:397.
18. Davies S.J., Goucher D.R., Doller C., Silver J. Robust regeneration of adult sensory axons in degenerating white matter of the adult rat spinal cord. J. Neurosci. 1999, 19:5810-5822.
19. De Preter K., De Brouwer S., Van Maerken T., Pattyn F., Schramm A., Eggert A., Vandesompele J., Speleman F. Meta-mining of neuroblastoma and neuroblast gene expression profiles reveals candidate therapeutic compounds. Clin. Cancer Res. 2009, 15:3690-3696.
20. Domeniconi M., Filbin M.T. Overcoming inhibitors in myelin to promote axonal regeneration. J. Neurol. Sci. 2005, 233:43-47.
21. Donohoe D.R., Weeks K., Aamodt E.J., Dwyer D.S. Antipsychotic drugs alter neuronal development including ALM neuroblast migration and PLM axonal outgrowth in Caenorhabditis elegans. Int. J. Dev. Neurosci. 2008, 26:371-380.
22. Dudok J.J., Groffen A.J., Witter M.P., Voorn P., Verhage M. Chronic activation of the 5-HT(2) receptor reduces 5-HT neurite density as studied in organotypic slice cultures. Brain Res. 2009, 1302:1-9.
23. Ernst H., Zanin M.K., Everman D., Hoffman S. Receptor-mediated adhesive and anti-adhesive functions of chondroitin sulfate proteoglycan preparations from embryonic chicken brain. J. Cell Sci. 1995, 108(Pt 12):3807-3816.
24. Feldkamp M.D., O'Donnell S.E., Yu L., Shea M.A. Allosteric effects of the antipsychotic drug trifluoperazine on the energetics of calcium binding by calmodulin. Proteins 2010, 78:2265-2282.
25. Filbin M.T. Myelin-associated inhibitors of axonal regeneration in the adult mammalian CNS. Nat. Rev. Neurosci. 2003, 4:703-713.
26. Gardner B., Strange P.G. Agonist action at D2(long) dopamine receptors: ligand binding and functional assays. Br. J. Pharmacol. 1998, 124:978-984.
27. George J., Dravid S.M., Prakash A., Xie J., Peterson J., Jabba S.V., Baden D.G., Murray T.F. Sodium channel activation augments NMDA receptor function and promotes neurite outgrowth in immature cerebrocortical neurons. J. Neurosci. 2009, 29:3288-3301.
28. Goldberg J.L., Klassen M.P., Hua Y., Barres B.A. Amacrine-signaled loss of intrinsic axon growth ability by retinal ganglion cells. Science 2002, 296:1860-1864.
29. Gullbo J., Fryknas M., Rickardson L., Darcy P., Hagg M., Wickstrom M., Hassan S., Westman G., Brnjic S., Nygren P., Linder S., Larsson R. Phenotype-based drug screening in primary ovarian carcinoma cultures identifies intracellular iron depletion as a promising strategy for cancer treatment. Biochem. Pharmacol. 2011, 82:139-147.
30. Hasegawa Y., Fujitani M., Hata K., Tohyama M., Yamagishi S., Yamashita T. Promotion of axon regeneration by myelin-associated glycoprotein and Nogo through divergent signals downstream of Gi/G. J. Neurosci. 2004, 24:6826-6832.
31. Hattori T., Shimizu S., Koyama Y., Yamada K., Kuwahara R., Kumamoto N., Matsuzaki S., Ito A., Katayama T., Tohyama M. DISC1 regulates cell-cell adhesion, cell-matrix adhesion and neurite outgrowth. Mol. Psychiatry 2010, 15(778):798-809.
32. Henley J.R., Huang K.H., Wang D., Poo M.M. Calcium mediates bidirectional growth cone turning induced by myelin-associated glycoprotein. Neuron 2004, 44:909-916.
33. 2+ that enhances neurite outgrowth in PC12 cells via activation of 5-HT3 receptors and voltage-gated calcium channels. J. Neurosci. Res. 2006, 84:316-325.
34. Huber A.B., Schwab M.E. Nogo-A, a potent inhibitor of neurite outgrowth and regeneration. Biol. Chem. 2000, 381:407-419.
35. Iorio L.C., Barnett A., Leitz F.H., Houser V.P., Korduba C.A. SCH 23390, a potential benzazepine antipsychotic with unique interactions on dopaminergic systems. J. Pharmacol. Exp. Ther. 1983, 226:462-468.
36. Jassen A.K., Yang H., Miller G.M., Calder E., Madras B.K. Receptor regulation of gene expression of axon guidance molecules: implications for adaptation. Mol. Pharmacol. 2006, 70:71-77.
37. Josset L., Textoris J., Loriod B., Ferraris O., Moules V., Lina B., N'guyen C., Diaz J.J., Rosa-Calatrava M. Gene expression signature-based screening identifies new broadly effective influenza a antivirals. PLoS One 2010, 5:e13169.
38. Karson C.N., Newton J.E.O., Mohanakrishnan P., Sprigg J., Komoroski R.A. Fluoxetine and trifluoperazine in human brain: a 19F-nuclear magnetic resonance spectroscopy study. Psychiatry Res.: Neuroimaging 1992, 45:95-104.
39. Kater S.B., Mills L.R. Regulation of growth cone behavior by calcium. J. Neurosci. 1991, 11:891-899.
40. Koprivica V., Cho K.S., Park J.B., Yiu G., Atwal J., Gore B., Kim J.A., Lin E., Tessier-Lavigne M., Chen D.F., He Z. EGFR activation mediates inhibition of axon regeneration by myelin and chondroitin sulfate proteoglycans. Science 2005, 310:106-110.
41. Kubo T., Yamaguchi A., Iwata N., Yamashita T. The therapeutic effects of Rho-ROCK inhibitors on CNS disorders. Ther. Clin. Risk Manage. 2008, 4:605-615.
42. Kuo T.Y., Chen C.Y., Hsueh Y.P. Bcl11A/CTIP1 mediates the effect of the glutamate receptor on axon branching and dendrite outgrowth. J. Neurochem. 2010, 114:1381-1392.
43. Kwon J.H., Eves E.M., Farrell S., Segovia J., Tobin A.J., Wainer B.H., Downen M. Beta-adrenergic receptor activation promotes process outgrowth in an embryonic rat basal forebrain cell line and in primary neurons. Eur. J. Neurosci. 1996, 8:2042-2055.
44. Lamb J., Crawford E.D., Peck D., Modell J.W., Blat I.C., Wrobel M.J., Lerner J., Brunet J.P., Subramanian A., Ross K.N., Reich M., Hieronymus H., Wei G., Armstrong S.A., Haggarty S.J., Clemons P.A., Wei R., Carr S.A., Lander E.S., Golub T.R. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 2006, 313:1929-1935.
45. Larson B.T., Samford M.D., Camden J.M., Piper E.L., Kerley M.S., Paterson J.A., Turner J.T. Ergovaline binding and activation of D2 dopamine receptors in GH4ZR7 cells. J. Anim. Sci. 1995, 73:1396-1400.
46. Lee J.K., Geoffroy C.G., Chan A.F., Tolentino K.E., Crawford M.J., Leal M.A., Kang B., Zheng B. Assessing spinal axon regeneration and sprouting in Nogo-, MAG-, and OMgp-deficient mice. Neuron 2010, 66:663-670.
47. Levin R.M., Weiss B. Mechanism by which psychotropic drugs inhibit adenosine cyclic 3',5'-monophosphate phosphodiesterase of brain. Mol. Pharmacol. 1976, 12:581-589.
48. Levine J.M. Increased expression of the NG2 chondroitin-sulfate proteoglycan after brain injury. J. Neurosci. 1994, 14:4716-4730.
49. Liu K., Lu Y., Lee J.K., Samara R., Willenberg R., Sears-Kraxberger I., Tedeschi A., Park K.K., Jin D., Cai B., Xu B., Connolly L., Steward O., Zheng B., He Z. PTEN deletion enhances the regenerative ability of adult corticospinal neurons. Nat. Neurosci. 2010, 13:1075-1081.
50. Lu X.H., Dwyer D.S. Second-generation antipsychotic drugs, olanzapine, quetiapine, and clozapine enhance neurite outgrowth in PC12 cells via PI3K/AKT, ERK, and pertussis toxin-sensitive pathways. J. Mol. Neurosci. 2005, 27:43-64.
51. Lynall M.E., Bassett D.S., Kerwin R., McKenna P.J., Kitzbichler M., Muller U., Bullmore E. Functional connectivity and brain networks in schizophrenia. J. Neurosci. 2010, 30:9477-9487.
52. Manion M.K., Villain M., Pan Z.G., McDonald J.M., Blalock J.E. Cellular uptake and in situ binding of a peptide agonist for calmodulin. Biochem. Biophys. Res. Commun. 2000, 277:462-469.
53. McKeon R.J., Schreiber R.C., Rudge J.S., Silver J. Reduction of neurite outgrowth in a model of glial scarring following CNS injury is correlated with the expression of inhibitory molecules on reactive astrocytes. J. Neurosci. 1991, 11:3398-3411.
54. McKeon R.J., Jurynec M.J., Buck C.R. The chondroitin sulfate proteoglycans neurocan and phosphacan are expressed by reactive astrocytes in the chronic CNS glial scar. J. Neurosci. 1999, 19:10778-10788.
55. McKerracher L., David S., Jackson D.L., Kottis V., Dunn R.J., Braun P.E. Identification of myelin-associated glycoprotein as a major myelin-derived inhibitor of neurite growth. Neuron 1994, 13:805-811.
56. McPheeters M.L., Warren Z., Sathe N., Bruzek J.L., Krishnaswami S., Jerome R.N., Veenstra-Vanderweele J. A systematic review of medical treatments for children with autism spectrum disorders. Pediatrics 2011, 127:e1312-e1321.
57. Meyer-Franke A., Kaplan M.R., Pfrieger F.W., Barres B.A. Characterization of the signaling interactions that promote the survival and growth of developing retinal ganglion cells in culture. Neuron 1995, 15:805-819.
58. Miyamoto S., Duncan G.E., Marx C.E., Lieberman J.A. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol. Psychiatry 2005, 10:79-104.
59. Miyoshi K., Honda A., Baba K., Taniguchi M., Oono K., Fujita T., Kuroda S., Katayama T., Tohyama M. Disrupted-In-Schizophrenia 1, a candidate gene for schizophrenia, participates in neurite outgrowth. Mol. Psychiatry 2003, 8:685-694.
60. Monnier P.P., Sierra A., Schwab J.M., Henke-Fahle S., Mueller B.K. The Rho/ROCK pathway mediates neurite growth-inhibitory activity associated with the chondroitin sulfate proteoglycans of the CNS glial scar. Mol. Cell. Neurosci. 2003, 22:319-330.
61. Moore D.L., Blackmore M.G., Hu Y., Kaestner K.H., Bixby J.L., Lemmon V.P., Goldberg J.L. KLF family members regulate intrinsic axon regeneration ability. Science 2009, 326:298-301.
62. Mosnaim A.D., Ranade V.V., Wolf M.E., Puente J., Antonieta Valenzuela M. Phenothiazine molecule provides the basic chemical structure for various classes of pharmacotherapeutic agents. Am. J. Ther. 2006, 13:261-273.
63. Mukhopadhyay G., Doherty P., Walsh F.S., Crocker P.R., Filbin M.T. A novel role for myelin-associated glycoprotein as an inhibitor of axonal regeneration. Neuron 1994, 13:757-767.
64. Munis J.R., Steiner J.T., Ruat M., Snyder S.H. Diamine oxidase induces neurite outgrowth in chick dorsal root ganglia by a nonenzymatic mechanism. J. Neurochem. 1998, 70:1323-1326.
65. Nord M., Farde L. Antipsychotic occupancy of dopamine receptors in schizophrenia. CNS Neurosci. Ther. 2011, 17:97-103.
66. Novak G., Tallerico T. Nogo A, B and C expression in schizophrenia, depression and bipolar frontal cortex, and correlation of Nogo expression with CAA/TATC polymorphism in 3'-UTR. Brain Res. 2006, 1120:161-171.
67. Novak G., Kim D., Seeman P., Tallerico T. Schizophrenia and Nogo: elevated mRNA in cortex, and high prevalence of a homozygous CAA insert. Brain Res. Mol. Brain Res. 2002, 107:183-189.
68. Ozeki Y., Tomoda T., Kleiderlein J., Kamiya A., Bord L., Fujii K., Okawa M., Yamada N., Hatten M.E., Snyder S.H., Ross C.A., Sawa A. Disrupted-in-Schizophrenia-1 (DISC-1): mutant truncation prevents binding to NudE-like (NUDEL) and inhibits neurite outgrowth. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:289-294.
69. Pae C.-U., Forbes A., Patkar A. Aripiprazole as adjunctive therapy for patients with major depressive disorder: overview and implications of clinical trial data. CNS Drugs 2011, 25:109-127.
70. Pantazopoulos H., Woo T.U., Lim M.P., Lange N., Berretta S. Extracellular matrix-glial abnormalities in the amygdala and entorhinal cortex of subjects diagnosed with schizophrenia. Arch. Gen. Psychiatry 2010, 67:155-166.
71. Park K.K., Liu K., Hu Y., Smith P.D., Wang C., Cai B., Xu B., Connolly L., Kramvis I., Sahin M., He Z. Promoting axon regeneration in the adult CNS by modulation of the PTEN/mTOR pathway. Science 2008, 322:963-966.
72. Polak K.A., Edelman A.M., Wasley J.W., Cohan C.S. A novel calmodulin antagonist, CGS 9343B, modulates calcium-dependent changes in neurite outgrowth and growth cone movements. J. Neurosci. 1991, 11:534-542.
73. Schmidt U., Beyer C., Oestreicher A.B., Reisert I., Schilling K., Pilgrim C. Activation of dopaminergic D1 receptors promotes morphogenesis of developing striatal neurons. Neuroscience 1996, 74:453-460.
74. Schmidt U., Pilgrim C., Beyer C. Differentiative effects of dopamine on striatal neurons involve stimulation of the cAMP/PKA pathway Mol. Cell. Neurosci. 1998, 11:9-18.
75. Shen Y., Tenney A.P., Busch S.A., Horn K.P., Cuascut F.X., Liu K., He Z., Silver J., Flanagan J.G. PTPsigma is a receptor for chondroitin sulfate proteoglycan, an inhibitor of neural regeneration. Science 2009, 326:592-596.
76. Sivasankaran R., Pei J., Wang K.C., Zhang Y.P., Shields C.B., Xu X.M., He Z. PKC mediates inhibitory effects of myelin and chondroitin sulfate proteoglycans on axonal regeneration. Nat. Neurosci. 2004, 7:261-268.
77. Skudlarski P., Jagannathan K., Anderson K., Stevens M.C., Calhoun V.D., Skudlarska B.A., Pearlson G. Brain connectivity is not only lower but different in schizophrenia: a combined anatomical and functional approach. Biol. Psychiatry 2010, 68:61-69.
78. Snow D.M., Lemmon V., Carrino D.A., Caplan A.I., Silver J. Sulfated proteoglycans in astroglial barriers inhibit neurite outgrowth in vitro. Exp. Neurol. 1990, 109:111-130.
79. Snow D.M., Atkinson P.B., Hassinger T.D., Letourneau P.C., Kater S.B. Chondroitin sulfate proteoglycan elevates cytoplasmic calcium in DRG neurons. Dev. Biol. 1994, 166:87-100.
80. Subramanian A., Tamayo P., Mootha V.K., Mukherjee S., Ebert B.L., Gillette M.A., Paulovich A., Pomeroy S.L., Golub T.R., Lander E.S., Mesirov J.P. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:15545-15550.
81. Tajima K., Fernandez H., Lopez-Ibor J.L., Carrasco J.L., Diaz-Marsa M. Schizophrenia treatment. Critical review on the drugs and mechanisms of action of antipsychotics. Actas Esp. Psiquiatr. 2009, 37:330-342.
82. Tanokura M., Yamada K. Effects of trifluoperazine on calcium binding by calmodulin. Heat capacity and entropy changes. J. Biol. Chem. 1986, 261:10749-10752.
83. Todd R.D. Neural development is regulated by classical neurotransmitters: dopamine D2 receptor stimulation enhances neurite outgrowth. Biol. Psychiatry 1992, 31:794-807.
84. Tripanichkul W., Stanic D., Drago J., Finkelstein D.I., Horne M.K. D2 dopamine receptor blockade results in sprouting of DA axons in the intact animal but prevents sprouting following nigral lesions. Eur. J. Neurosci. 2003, 17:1033-1045.
85. Ughrin Y.M., Chen Z.J., Levine J.M. Multiple regions of the NG2 proteoglycan inhibit neurite growth and induce growth cone collapse. J. Neurosci. 2003, 23:175-186.
86. Usher L.C., Johnstone A., Erturk A., Hu Y., Strikis D., Wanner I.B., Moorman S., Lee J.W., Min J., Ha H.H., Duan Y., Hoffman S., Goldberg J.L., Bradke F., Chang Y.T., Lemmon V.P., Bixby J.L. A chemical screen identifies novel compounds that overcome glial-mediated inhibition of neuronal regeneration. J. Neurosci. 2010, 30:4693-4706.
87. Van Vliet B.J., Mulder A.H., Schoffelmeer A.N. Mu-opioid receptors mediate the inhibitory effect of opioids on dopamine-sensitive adenylate cyclase in primary cultures of rat neostriatal neurons. J. Neurochem. 1990, 55:1274-1280.
88. VanDeMark K.L., Guizzetti M., Giordano G., Costa L.G. The activation of M1 muscarinic receptor signaling induces neuronal differentiation in pyramidal hippocampal neurons. J. Pharmacol. Exp. Ther. 2009, 329:532-542.
89. Vandonselaar M., Hickie R.A., Quail J.W., Delbaere L.T. Trifluoperazine-induced conformational change in Ca(2+)-calmodulin. Nat. Struct. Biol. 1994, 1:795-801.
90. Vilar E., Mukherjee B., Kuick R., Raskin L., Misek D.E., Taylor J.M., Giordano T.J., Hanash S.M., Fearon E.R., Rennert G., Gruber S.B. Gene expression patterns in mismatch repair-deficient colorectal cancers highlight the potential therapeutic role of inhibitors of the phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin pathway. Clin. Cancer Res. 2009, 15:2829-2839.
91. Villain M., Jackson P.L., Manion M.K., Dong W.J., Su Z., Fassina G., Johnson T.M., Sakai T.T., Krishna N.R., Blalock J.E. De novo design of peptides targeted to the EF hands of calmodulin. J. Biol. Chem. 2000, 275:2676-2685.
92. Walmsley A.R., Mir A.K. Targeting the Nogo-A signalling pathway to promote recovery following acute CNS injury. Curr. Pharm. Des. 2007, 13:2470-2484.
93. Wang K.C., Koprivica V., Kim J.A., Sivasankaran R., Guo Y., Neve R.L., He Z. Oligodendrocyte-myelin glycoprotein is a Nogo receptor ligand that inhibits neurite outgrowth. Nature 2002, 417:941-944.
94. Wang J.T., Kunzevitzky N.J., Dugas J.C., Cameron M., Barres B.A., Goldberg J.L. Disease gene candidates revealed by expression profiling of retinal ganglion cell development. J. Neurosci. 2007, 27:8593-8603.
95. Wang G., Ye Y., Yang X., Liao H., Zhao C., Liang S. Expression-based in silico screening of candidate therapeutic compounds for lung adenocarcinoma. PLoS One 2011, 6:e14573.
96. Weiss B., Prozialeck W., Cimino M., Barnette M.S., Wallace T.L. Pharmacological regulation of calmodulin. Ann. N. Y. Acad. Sci. 1980, 356:319-345.
97. Yiu G., He Z. Signaling mechanisms of the myelin inhibitors of axon regeneration. Curr. Opin. Neurobiol. 2003, 13:545-551.
98. Zalesky A., Fornito A., Seal M.L., Cocchi L., Westin C.F., Bullmore E.T., Egan G.F., Pantelis C. Disrupted axonal fiber connectivity in schizophrenia. Biol. Psychiatry 2011, 69:80-89.